Orbimed Advisors Stake in Immunomedics (IMMU) Boosted by $65.88 Million; Novare Capital Management Has Trimmed Amern Tower Class A (AMT) Holding by $360,400

January 20, 2018 - By Hazel Jackson

Novare Capital Management Llc decreased its stake in Amern Tower Corp Class A (AMT) by 7.18% based on its latest 2017Q3 regulatory filing with the SEC. Novare Capital Management Llc sold 2,650 shares as the company’s stock rose 18.69% with the market. The institutional investor held 34,257 shares of the real estate investment trusts company at the end of 2017Q3, valued at $4.68M, down from 36,907 at the end of the previous reported quarter. Novare Capital Management Llc who had been investing in Amern Tower Corp Class A for a number of months, seems to be less bullish one the $59.02B market cap company. The stock increased 1.80% or $2.43 during the last trading session, reaching $137.62. About 3.28M shares traded or 51.04% up from the average. American Tower Corporation (NYSE:AMT) has risen 23.66% since January 20, 2017 and is uptrending. It has outperformed by 6.96% the S&P500.

Samuel Isaly increased its stake in Immunomedics Inc (IMMU) by 102.82% based on its latest 2017Q3 regulatory filing with the SEC. Orbimed Advisors Llc bought 5.07 million shares as the company’s stock rose 37.64% with the market. The hedge fund run by Samuel Isaly held 10.00M shares of the health care company at the end of 2017Q3, valued at $139.76 million, up from 4.93 million at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Immunomedics Inc for a number of months, seems to be bullish on the $2.57B market cap company. The stock increased 0.95% or $0.15 during the last trading session, reaching $15.99. About 1.50M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since January 20, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Tuesday, June 21 by Wells Fargo. The company was downgraded on Wednesday, July 29 by Jefferies. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Friday, May 6 by Jefferies. Jefferies maintained the stock with “Buy” rating in Friday, June 9 report. The stock has “Buy” rating by Jefferies on Thursday, October 6. Jefferies maintained it with “Hold” rating and $1.50 target in Tuesday, March 15 report. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Wednesday, December 6 with “Buy” rating. On Thursday, August 17 the stock rating was maintained by Jefferies with “Buy”. Cowen & Co maintained it with “Buy” rating and $15.0 target in Wednesday, December 6 report. Cowen & Co maintained the shares of IMMU in report on Wednesday, August 16 with “Buy” rating.

Orbimed Advisors Llc, which manages about $6.70B and $10.46 billion US Long portfolio, decreased its stake in Glaukos Corp by 905,200 shares to 836,500 shares, valued at $27.61 million in 2017Q3, according to the filing. It also reduced its holding in Gilead Sciences Inc (NASDAQ:GILD) by 145,400 shares in the quarter, leaving it with 1.93M shares, and cut its stake in Envision Healthcare Corp.

Investors sentiment increased to 1.65 in 2017 Q3. Its up 0.24, from 1.41 in 2017Q2. It improved, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Nationwide Fund Advsrs invested in 56,912 shares. Royal Bancorporation Of Canada invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Price T Rowe Assocs Inc Md, Maryland-based fund reported 6.38 million shares. Axiom Int Ltd Liability Company De reported 0.06% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Deutsche Commercial Bank Ag holds 1.39M shares or 0.01% of its portfolio. Art Limited Liability Corp accumulated 122,500 shares. Wells Fargo & Mn holds 294,565 shares or 0% of its portfolio. Rhenman & Ptnrs Asset Mgmt accumulated 0.89% or 500,000 shares. Adage Capital Partners Grp Limited Company stated it has 161,000 shares or 0.01% of all its holdings. Advisory Services Ltd reported 0% in Immunomedics, Inc. (NASDAQ:IMMU). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Lpl Financial Limited Liability Company has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Bnp Paribas Arbitrage accumulated 10,311 shares or 0% of the stock. Creative Planning holds 0.12% or 1.87M shares. Spectrum Group Inc invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU).

Since August 21, 2017, it had 0 insider purchases, and 6 selling transactions for $2.10 million activity. 20,000 Immunomedics, Inc. (NASDAQ:IMMU) shares with value of $252,750 were sold by GOLDENBERG CYNTHIA L.

Among 19 analysts covering American Tower Corporation (NYSE:AMT), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. American Tower Corporation had 68 analyst reports since August 6, 2015 according to SRatingsIntel. Morgan Stanley maintained the shares of AMT in report on Thursday, August 24 with “Overweight” rating. Guggenheim upgraded American Tower Corporation (NYSE:REIT) on Tuesday, April 11 to “Buy” rating. The stock of American Tower Corporation (NYSE:REIT) has “Buy” rating given on Monday, October 2 by RBC Capital Markets. Macquarie Research maintained American Tower Corporation (NYSE:REIT) rating on Monday, November 9. Macquarie Research has “Outperform” rating and $115 target. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 13. Citigroup maintained American Tower Corporation (NYSE:REIT) on Wednesday, August 10 with “Buy” rating. Oppenheimer maintained the stock with “Buy” rating in Wednesday, December 20 report. The stock has “Buy” rating by Stifel Nicolaus on Monday, October 31. On Monday, June 12 the stock rating was downgraded by Raymond James to “Outperform”. As per Thursday, June 8, the company rating was maintained by RBC Capital Markets.

Novare Capital Management Llc, which manages about $695.33 million and $568.22M US Long portfolio, upped its stake in Vanguard Emerging Markets (VWO) by 16,074 shares to 97,220 shares, valued at $4.24 million in 2017Q3, according to the filing. It also increased its holding in Facebook Inc Class A (NASDAQ:FB) by 1,845 shares in the quarter, for a total of 43,131 shares, and has risen its stake in Realty Income (NYSE:O).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com